52031-05-7

Usage

Chemical Properties

white powder

InChI:InChI=1/C11H14ClNO2/c1-2-15-11(14)10(13)7-8-3-5-9(12)6-4-8/h3-6,10H,2,7,13H2,1H3/p+1/t10-/m0/s1

Upstream product

• 64-17-5 ethanol 
• 7424-00-2 DL-Phe(4Cl) 
• 69555-14-2 ethyl N-diphenylmethylene glycine 
• 104-83-6 1-Chloro-4-(chloromethyl)benzene 
• 104-88-1 4-chlorobenzaldehyde 
• 6941-36-2 2-acetylamino-2-(4-chlorobenzyl)malonic acid diethyl ester 
• 23633-07-0 2-amino-3-(4-chlorophenyl)propionic acid hydrochloride 
• 84713-70-2 N-(4-chlorophenyl)methyleneglycine ethyl ester 
• 622-95-7 4-chlorobenzyl bromide 

Downstream Products

• 1374334-32-3 (±)-7-chloro-3,4-dihydro-2(1H)-(1,1-dimethylethoxy)carbonylisoquinoline-3-carboxylic acid 
• 51366-22-4 D,L-4-chlorophenylalanine ethyl ester hydrochloride 
• 51366-21-3 C₁₁H₁₄ClNO₂*ClH 
• 870266-03-8 2-[(2-biphenyl-4-yl-6-methyl-pyrimidine-4-carbonyl)amino]-3-(4-chloro-phenyl)propionic acid ethyl ester 
• 856571-34-1 3-(4-chlorophenyl)-2-{2-[(1H-indole-2-carbonyl)amino]benzoylamino}propionic acid ethyl ester 
• 7424-00-2 DL-Phe(4Cl) 
• 14173-39-8 p-chlorophenylalanine 
• 166449-97-4 D-4-chlorophenylalanine ethyl ester 

Relevant academic research and scientific papers

Anthranilic acid based CCK1 receptor antagonists: Preliminary investigation on their second "touch point"

In this phase of structure-affinity relationship study of VL-0395, a new anthranilic acid based CCK1 selective antagonist, we propose a series of unnatural aminoacidic derivatives. The result of this work is the identification of a new CCK ligand, which possesses an affinity (IC50 = 35 nm) one order of magnitude greater than the lead and, as a general rule, it points out how the hypothesized receptorial pocket which accommodates the Phe residue allows much more structural modification than that interacting with the N-terminal group. Hence, the modification of the C-terminal pharmacophoric group of our lead VL-0395 can not only enhance the affinity of anthranilic acid derivatives but can modulate the selectivity for one CCK receptor subtype or afford mixed antagonists.

Synthesis and antitumor activity of platinum(II) complexes containing substituted ethylenediamine ligands

The synthesis of substituted ethylenediamines, their reactions with K2PtCl4 to give the dichloroplatinum(II) complexes, and the exchange of the chloro ligands for other leaving groups are described.The new compounds have been tested as antitumor agents both in vitro using the hormone independent human mammary carcinoma cell line MDA-MB 231 as well as in vivo using the lymphocytic P388 leukemia of the CD2F1-mouse.In the P388 test, 53 of the 55 tested complexes fulfill the minimum activity of 125percent T/C required for a substance to be active.

SYNTHESIS OF AMINO ACIDS. ALKYLATION OF ALDIMINE AND KETIMINE DERIVATIVES OF GLYCINE ETHYL ESTER UNDER VARIOUS PHASE-TRANSFER CONDITIONS

The Schiff base derived from glycine ethyl ester and p-chlorobenzaldehyde can be alkylated by the ion-pair extraction method as well as under catalytic liquid-liquid or solid-liquid phase-transfer conditions.This imine is compared with the corresponding benzophenone Schiff base.